Putting new CARs in the spotlight

As we move on from second generation CAR-T cell therapies and CRISPR gene editing as well as a DNA to RNA shift, there’s a noticeable coming together of these modalities in novel next generation ideas now entering early stage trials in the clinic.

Inevitably some will fail, others will meet with mixed reactions on modest data, but a few will succeed and inspire the next round of innovative approaches.

Are there early signs of which products/companies might fall into each bucket?

Here we highlight fourteen examples to watch out for across biotechs and pharma alike while discussing some of the opportunities and challenges they may face…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by